Page last updated: 2024-08-25

tellimagrandin i and Uterine Cervical Neoplasms

tellimagrandin i has been researched along with Uterine Cervical Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fan, YB; Li, HX; Liu, YZ; Wang, Z; Yi, ZC; Yin, Y; Zhuang, FY	1

Other Studies

1 other study(ies) available for tellimagrandin i and Uterine Cervical Neoplasms

Article	Year
Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro. Cancer letters, 2006, Oct-08, Volume: 242, Issue:1 Topics: Antineoplastic Agents; Connexin 43; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluoresceins; Gallic Acid; Gap Junctions; Gene Expression Regulation, Neoplastic; Glucosides; HeLa Cells; Humans; Hydrolyzable Tannins; In Vitro Techniques; Isoquinolines; Phenotype; Uterine Cervical Neoplasms	2006

Article

Year

Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro.

Cancer letters, 2006, Oct-08, Volume: 242, Issue:1

Topics: Antineoplastic Agents; Connexin 43; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluoresceins; Gallic Acid; Gap Junctions; Gene Expression Regulation, Neoplastic; Glucosides; HeLa Cells; Humans; Hydrolyzable Tannins; In Vitro Techniques; Isoquinolines; Phenotype; Uterine Cervical Neoplasms

2006